ELSEVIER


Contents lists available at ScienceDirect

EBioMedicine

journal homepage: www.elsevier.com/locate/ebiom



Erratum





Jiwei Guo^{a,1}, Dan Jin^{b,1}, Yan Wu^a, Lijuan Yang^a, Jing Du^a, Kaikai Gong^a, Weiwei Chen^a, Juanjuan Dai^a, Shuang Miao^a, Sichuan Xi^a

This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy).

This article has been retracted at the request of the Authors. After publication of our EBioMedicine article [1], several concerns were raised with respect to the veracity of the data. Evidence of image duplication was found within figures relating to the transwell assays, scratch assays, immunohistochemistry images, and clone formation assays. The corresponding author Jiwei Guo and all co-authors would like to withdraw this article to maintain the integrity of the scientific record. The authors sincerely apologise to the editors and journal

readership for these oversights and inconvenience that this may have caused.

EBioMedicine Editors

Reference

[1] Guo J, et al. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells. EBioMedicine 2018;35:204–21.

^a Cancer research institute, Binzhou Medical University Hospital, Binzhou 256603, PR China

^b Department of Pain Management, Binzhou Medical University Hospital, Binzhou 256603, PR China

DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2018.08.001. *E-mail address*:

¹ These authors contributed equally to this work.